HRH3 and myelodysplastic syndrome: This finding prompted us to test the activity of the histamine H3 receptor antagonist, pitolisant (Fabara, Ortiz et al. 2021, Sarfraz, Okuampa et al. 2022), in correcting observed behavioral deficits in a mouse model of MDS.